학술논문

Epigenetic regulation in cancer
Document Type
Report
Source
MedComm. February 2024, Vol. 5 Issue 2
Subject
Development and progression
Genetic aspects
Epigenetic inheritance -- Genetic aspects
Cancer -- Development and progression -- Genetic aspects
Genes -- Genetic aspects
Methylation
Amino acids -- Genetic aspects
Genomes -- Genetic aspects
Genomics -- Genetic aspects
Chromatin -- Genetic aspects
Gene mutation -- Genetic aspects
DNA sequencing -- Genetic aspects
DNA -- Genetic aspects
Enzymes -- Genetic aspects
Cancer metastasis -- Genetic aspects -- Development and progression
Gene expression -- Genetic aspects
Gene mutations -- Genetic aspects
Nucleotide sequencing -- Genetic aspects
Metastasis -- Genetic aspects -- Development and progression
Language
English
Abstract
INTRODUCTION In a seminal conceptualization by Conrad Waddington, the term “epigenetics” was introduced to encapsulate the phenomenon whereby alterations in cellular phenotype are inherited across generations, independent of DNA sequence [...]
: Epigenetic modifications are defined as heritable changes in gene activity that do not involve changes in the underlying DNA sequence. The oncogenic process is driven by the accumulation of alterations that impact genome's structure and function. Genetic mutations, which directly disrupt the DNA sequence, are complemented by epigenetic modifications that modulate gene expression, thereby facilitating the acquisition of malignant characteristics. Principals among these epigenetic changes are shifts in DNA methylation and histone mark patterns, which promote tumor development and metastasis. Notably, the reversible nature of epigenetic alterations, as opposed to the permanence of genetic changes, positions the epigenetic machinery as a prime target in the discovery of novel therapeutics. Our review delves into the complexities of epigenetic regulation, exploring its profound effects on tumor initiation, metastatic behavior, metabolic pathways, and the tumor microenvironment. We place a particular emphasis on the dysregulation at each level of epigenetic modulation, including but not limited to, the aberrations in enzymes responsible for DNA methylation and histone modification, subunit loss or fusions in chromatin remodeling complexes, and the disturbances in higher‐order chromatin structure. Finally, we also evaluate therapeutic approaches that leverage the growing understanding of chromatin dysregulation, offering new avenues for cancer treatment.